Prices are falling for the popular obesity treatments semaglutide (Wegovy) and tirzepatide (Zepbound), but steady access to the drugs remains challenging. The medications still amount to around $500 ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Tirzepatide could result in net lifetime health care costs of more than $16 trillion in the U.S. if all people eligible to ...

When we feed the body correctly, we can influence the same systems that drugs like Mounjaro target - helping regulate ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Joie Armstrong asked her doctor about taking a GLP-1 medication to help her lose weight six times before she got a prescription, and then was denied coverage by her insurance company. Adrian, a ...

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...